Avanos Medical (NYSE:AVNS) Hits New 52-Week Low - Should You Sell?

Avanos Medical, Inc. (NYSE:AVNS - Get Free Report) reached a new 52-week low during trading on Monday . The company traded as low as $12.57 and last traded at $13.22, with a volume of 343 shares traded. The stock had previously closed at $13.42.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Avanos Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th.

Avanos Medical Stock Up 0.3 %

The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46. The stock has a market capitalization of $573.61 million, a price-to-earnings ratio of 36.67 and a beta of 1.15. The firm's fifty day moving average is $14.86 and its 200-day moving average is $17.50.

Avanos Medical (NYSE:AVNS - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.03. The business had revenue of $179.60 million for the quarter, compared to analyst estimates of $177.23 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. On average, sell-side analysts predict that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.

Insider Transactions at Avanos Medical

In related news, SVP Kerr Holbrook sold 7,000 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total transaction of $106,750.00. Following the sale, the senior vice president now owns 82,047 shares in the company, valued at $1,251,216.75. This represents a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.64% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company grew its position in Avanos Medical by 34.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,996 shares of the company's stock valued at $553,000 after buying an additional 5,859 shares in the last quarter. FMR LLC boosted its holdings in shares of Avanos Medical by 34.6% in the third quarter. FMR LLC now owns 133,844 shares of the company's stock valued at $3,216,000 after acquiring an additional 34,421 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Avanos Medical by 12.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 108,470 shares of the company's stock valued at $2,607,000 after acquiring an additional 11,613 shares during the period. Jane Street Group LLC lifted its position in Avanos Medical by 35.8% in the third quarter. Jane Street Group LLC now owns 65,650 shares of the company's stock worth $1,578,000 after purchasing an additional 17,306 shares during the period. Finally, EP Wealth Advisors LLC bought a new position in Avanos Medical during the 3rd quarter valued at $212,000. Institutional investors own 95.17% of the company's stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.